Loading...
XNAS
CGEN
Market cap148mUSD
Jul 11, Last price  
1.59USD
1D
-5.92%
1Q
26.19%
Jan 2017
-68.82%
IPO
-85.70%
Name

Compugen Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
5.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.07%
Rev. gr., 5y
13.45%
Revenues
28m
-16.72%
646,000215,000180,000338,000250,0001,115,000-424,000242,0003,549,00012,367,0009,277,000712,000017,800,00002,000,0006,000,0007,500,00033,459,00027,864,000
Net income
-14m
L-24.12%
-13,978,000-13,020,000-12,114,000-12,527,000-3,831,000-7,203,000-12,004,000-13,628,000-14,083,000-11,094,000-20,163,000-31,506,000-37,066,000-22,599,000-27,337,000-27,260,000-32,873,000-33,694,000-18,754,000-14,231,000
CFO
50m
P
-11,108,000-9,933,000-8,407,000-10,012,000-7,453,000-4,279,000-9,249,000-10,846,000-6,439,000-11,148,000-25,607,000-19,819,000-30,658,000-13,291,000-27,888,000-28,320,000-22,750,000-34,506,000-35,886,00049,604,000
Earnings
Aug 04, 2025

Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
URL
https://cgen.com/
IPO date
Aug 01, 2000
Employees
69
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
27,864
-16.72%
33,459
346.12%
7,500
25.00%
Cost of revenue
42,755
46,451
42,874
Unusual Expense (Income)
NOPBT
(14,891)
(12,992)
(35,374)
NOPBT Margin
Operating Taxes
4,522
8,970
58
Tax Rate
NOPAT
(19,413)
(21,962)
(35,432)
Net income
(14,231)
-24.12%
(18,754)
-44.34%
(33,694)
2.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
544
3,081
353
BB yield
-0.40%
-1.78%
-0.57%
Debt
Debt current
448
632
613
Long-term debt
5,376
2,070
3,237
Deferred revenue
34,045
25,392
Other long-term liabilities
3,412
3,398
3,265
Net debt
(97,431)
(47,983)
(79,858)
Cash flow
Cash from operating activities
49,604
(35,886)
(34,506)
CAPEX
(118)
(172)
(487)
Cash from investing activities
(46,252)
35,510
37,060
Cash from financing activities
554
3,081
353
FCF
17,697
(59,409)
(34,885)
Balance
Cash
103,255
50,685
83,708
Long term investments
Excess cash
101,862
49,012
83,333
Stockholders' equity
(488,499)
(474,278)
(455,533)
Invested Capital
583,782
569,978
538,403
ROIC
ROCE
EV
Common stock shares outstanding
89,528
87,633
86,556
Price
1.53
-22.73%
1.98
176.65%
0.72
-83.36%
Market cap
136,978
-21.06%
173,514
180.10%
61,948
-82.89%
EV
39,547
125,531
(17,910)
EBITDA
(14,405)
(12,516)
(34,892)
EV/EBITDA
0.51
Interest
1,713
31
27
Interest/NOPBT